BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34559266)

  • 1. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin.
    Quigley NG; Steiger K; Hoberück S; Czech N; Zierke MA; Kossatz S; Pretze M; Richter F; Weichert W; Pox C; Kotzerke J; Notni J
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1136-1147. PubMed ID: 34559266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of In-House Kit-Like Synthesis of
    Thakral P; Das SS; Dhiman S; Manda D; Virupakshappa CB; Malik D; Sen I
    Cancer Biother Radiopharm; 2023 Sep; 38(7):468-474. PubMed ID: 37093129
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential Efficacy of 68Ga-Trivehexin PET/CT and Immunohistochemical Validation of αvβ6 Integrin Expression in Patients With Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma.
    Das SS; Ahlawat S; Thakral P; Malik D; Simecek J; Cb V; Koley M; Gupta J; Sen I
    Clin Nucl Med; 2024 May; ():. PubMed ID: 38768077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the RGD Motif-Containing α
    Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
    J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT Imaging of NSCLC with a α
    Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
    Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo PET Imaging of the Cancer Integrin αvβ6 Using
    Notni J; Reich D; Maltsev OV; Kapp TG; Steiger K; Hoffmann F; Esposito I; Weichert W; Kessler H; Wester HJ
    J Nucl Med; 2017 Apr; 58(4):671-677. PubMed ID: 27980050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Translation of a
    Feng X; Wang Y; Lu D; Xu X; Zhou X; Zhang H; Zhang T; Zhu H; Yang Z; Wang F; Li N; Liu Z
    J Nucl Med; 2020 Oct; 61(10):1461-1467. PubMed ID: 32086242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin.
    Notni J; Steiger K; Hoffmann F; Reich D; Kapp TG; Rechenmacher F; Neubauer S; Kessler H; Wester HJ
    J Nucl Med; 2016 Mar; 57(3):460-6. PubMed ID: 26635338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a
    Ui T; Ueda M; Higaki Y; Kamino S; Sano K; Kimura H; Saji H; Enomoto S
    Bioorg Med Chem; 2020 Jan; 28(1):115189. PubMed ID: 31740201
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ren J; Zhu S; Zhang G; Tan X; Qiu L; Lin J; Jiang L
    Mol Pharm; 2022 Jul; 19(7):2620-2628. PubMed ID: 35674464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins.
    Monieri M; Rainone P; Sacchi A; Gori A; Gasparri AM; Coliva A; Citro A; Ferrara B; Policardi M; Valtorta S; Pocaterra A; Alfano M; Sheppard D; Piemonti L; Moresco RM; Corti A; Curnis F
    Int J Biol Sci; 2023; 19(1):156-166. PubMed ID: 36594095
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement of biodistribution profile of a radiogallium-labeled, αvβ6 integrin-targeting peptide probe by incorporation of negatively charged amino acids.
    Nakamura S; Matsuno A; Ueda M
    Ann Nucl Med; 2020 Aug; 34(8):575-582. PubMed ID: 32514725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evaluation of
    Ganguly T; Bauer N; Davis RA; Foster CC; Harris RE; Hausner SH; Roncali E; Tang SY; Sutcliffe JL
    J Nucl Med; 2023 Apr; 64(4):639-644. PubMed ID: 36207137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an Integrin α
    Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
    Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of a dual-receptor targeted tracer [
    Lv X; Song X; Long Y; Zeng D; Lan X; Gai Y
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):54-67. PubMed ID: 37642706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [
    Lobeek D; Rijpkema M; Terry SYA; Molkenboer-Kuenen JDM; Joosten L; van Genugten EAJ; van Engen-van Grunsven ACH; Kaanders JHAM; Pegge SAH; Boerman OC; Weijs WLJ; Merkx MAW; van Herpen CML; Takes RP; Aarntzen EHJG; Oyen WJG
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2647-2655. PubMed ID: 32198613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography.
    Steiger K; Quigley NG; Groll T; Richter F; Zierke MA; Beer AJ; Weichert W; Schwaiger M; Kossatz S; Notni J
    EJNMMI Res; 2021 Oct; 11(1):106. PubMed ID: 34636990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366.
    D'Alessandria C; Pohle K; Rechenmacher F; Neubauer S; Notni J; Wester HJ; Schwaiger M; Kessler H; Beer AJ
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):953-963. PubMed ID: 26497698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes.
    Floresta G; Memdouh S; Pham T; Ma MT; Blower PJ; Hider RC; Abbate V; Cilibrizzi A
    Dalton Trans; 2022 Aug; 51(34):12796-12803. PubMed ID: 35972045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin αvβ6.
    Hackel BJ; Kimura RH; Miao Z; Liu H; Sathirachinda A; Cheng Z; Chin FT; Gambhir SS
    J Nucl Med; 2013 Jul; 54(7):1101-5. PubMed ID: 23670900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.